Based on these data, the Food and Drug Administration (FDA) approved pembrolizumab 2021 as first-line therapy in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥ 1). This evidence concerns the gene CD274 and cervical cancer.